# CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1

> **NCT02504008** · PHASE3 · UNKNOWN · sponsor: **Axsome Therapeutics, Inc.** · enrollment: 190 (estimated)

## Conditions studied

- Complex Regional Pain Syndrome
- Reflex Sympathetic Dystrophy

## Interventions

- **DRUG:** AXS-02 (oral zoledronate)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02504008
- **Lead sponsor:** Axsome Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-07
- **Primary completion:** 2019-01
- **Final completion:** 2019-01
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2018-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02504008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02504008, "CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT02504008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*